Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | PTGIR | P43119 | 2/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856597 | 1.00 | JAK2 (0.37) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL5696892 | 0.87 | ALDH1A1 (0.43) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL6256094 | 0.87 | — | — | |
| SCHEMBL17029138 | 0.87 | ALDH1A1 (0.43) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL5682344 | 0.86 | JAK2 (0.34) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL5680239 | 0.83 | ALDH1A1 (0.35) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL5682481 | 0.82 | ALDH1A1 (0.34) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL17444411 | 0.80 | SLC1A3 (0.38) | LMNASLC1A3SLC1A2SLC1A1PTGIR | |
| SCHEMBL17444410 | 0.80 | SLC1A3 (0.38) | LMNASLC1A3SLC1A2SLC1A1PTGIR | |
| SCHEMBL17449195 | 0.80 | LMNA (0.42) | JAK2JAK1TYK2JAK3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230089916-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-2638006-A1 | HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Achaogen, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012154204-A1 | HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | ACHAOGEN, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154204-A1 | HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | ACHAOGEN, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | JAK2 184/4885JAK1 165/4885TYK2 21/4885 |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | JAK2 1427/4885JAK1 3170/4885TYK2 2999/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | JAK2 184/4885JAK1 165/4885TYK2 21/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | JAK2 184/4885JAK1 165/4885TYK2 21/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | JAK2 1853/4885JAK1 2788/4885TYK2 3333/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | JAK2 184/4885JAK1 165/4885TYK2 21/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | JAK2 184/4885JAK1 165/4885TYK2 21/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | JAK2 1427/4885JAK1 3170/4885TYK2 2999/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | JAK2 184/4885JAK1 165/4885TYK2 21/4885 |
| US-20230089916-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | JAK2 720/4885JAK1 732/4885TYK2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.